Please access the PDF below to read the response to the FDA safety communication on March 31, 2021, titled Acellular Dermal Matrix (ADM) Products Used in Implant-Based Breast Reconstruction Differ in Complication Rates.
PDF: In Re: FDA Safety Communication on March 31, 2021 titled Acellular Dermal Matrix (ADM) Products Used in Implant-Based Breast Reconstruction Differ in Complication RatesĀ - April 7, 2021